Related Experiment Video
Updated: Jan 22, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
A cardiovascular risk prediction model for older people: Development and validation in a primary care population
Emma F van Bussel1, Edo Richard2,3, Wim B Busschers1
1Department of General Practice, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Insights
Traditional cardiovascular risk factors like cholesterol and blood pressure are less effective in older adults. New predictors include polypharmacy and apathy, improving cardiovascular disease (CVD) risk prediction in the elderly.
Area of Science:
- Gerontology
- Cardiology
- Epidemiology
Background:
- Traditional cardiovascular disease (CVD) risk factors are validated in middle-aged populations.
- Their predictive power for CVD attenuates in older adults.
- Accurate CVD risk prediction in the elderly requires updated models considering age-specific factors and competing risks.
Purpose of the Study:
- To develop and validate CVD risk prediction models for older adults.
- To re-evaluate traditional and identify novel risk factors for CVD in this demographic.
- To assess the impact of competing non-cardiovascular mortality risks on CVD prediction.
Main Methods:
- Post hoc analysis of 1811 participants (aged 70-78) from the preDIVA study.
- Cox-regression and Fine-Gray models were used to assess traditional and new risk factors.
- Models were compared with and without accounting for competing risks of death.
Main Results:
- Age, sex, smoking, and type 2 diabetes mellitus predicted CVD.
- Systolic blood pressure, HDL-cholesterol, and total cholesterol did not predict CVD in this cohort.
- Polypharmacy and apathy symptoms emerged as significant novel predictors of CVD.
- Model discrimination was moderate (concordance statistic 0.65).
Conclusions:
- Traditional risk factors like SBP, HDL, and total cholesterol are not predictive of CVD in older adults.
- Polypharmacy and apathy symptoms are new, relevant predictors for CVD in this age group.
- Incorporating these factors can enhance CVD risk prediction and targeted prevention in older populations.
Abstract:
Cardiovascular risk prediction is mainly based on traditional risk factors that have been validated in middle-aged populations. However, associations between these risk factors and cardiovascular disease (CVD) attenuate with increasing age. Therefore, for older people the authors developed and internally validated risk prediction models for fatal and non-fatal CVD, (re)evaluated the predictive value of traditional and new factors, and assessed the impact of competing risks of non-cardiovascular death. Post hoc analyses of 1811 persons aged 70-78 year and free from CVD at baseline from the preDIVA study (Prevention of Dementia by Intensive Vascular care, 2006-2015), a primary care-based trial that included persons free from dementia and conditions likely to hinder successful long-term follow-up, were performed. In 2017-2018, Cox-regression analyses were performed for a model including seven traditional risk factors only, and a model to assess incremental predictive ability of the traditional and eleven new factors. Analyses were repeated accounting for competing risk of death, using Fine-Gray models. During an average of 6.2 years of follow-up, 277 CVD events occurred. Age, sex, smoking, and type 2 diabetes mellitus were traditional predictors for CVD, whereas total cholesterol, HDL-cholesterol, and systolic blood pressure (SBP) were not. Of the eleven new factors, polypharmacy and apathy symptoms were predictors. Discrimination was moderate (concordance statistic 0.65). Accounting for competing risks resulted in slightly smaller predicted absolute risks. In conclusion, we found, SBP, HDL, and total cholesterol no longer predict CVD in older adults, whereas polypharmacy and apathy symptoms are two new relevant predictors. Building on the selected risk factors in this study may improve CVD prediction in older adults and facilitate targeting preventive interventions to those at high risk.
Related Concept Videos
Reliability and Validity
Conservation of Small Populations
In Vitro Drug Release Testing: Overview, Development and Validation
Predicting Molecular Geometry
What is Population Genetics?
Population Growth

